Mazumdar Claire
SEC CIK 2034671 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | CEO, Dir | 372.2K | — | $4.06M | 21 | 2025-10-13 | 2026-08-10 |
Most active insiders at BCAX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | $4.80M | — |
| 2 | Cohlhepp Ryan | Pres, COO, Interim CEO, Dir | — | $4.60M |
| 3 | Mazumdar Claire | CEO, Dir | — | $4.06M |
| 4 | Hyep Ivan | CFO | — | $3.24M |
| 5 | Raben David | Chief Medical Off | — | $1.15M |
| 6 | Meisner Lara | CLO | — | $498.7K |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +10.0K | 372.2K | +3% | +$37.9K |
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $27.98 | -10.0K | 362.2K | -3% | -$279.8K |
| DT | 2026-07-14 16:22 | 2026-07-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +10.0K | 372.2K | +3% | +$37.9K |
| DMT | 2026-07-14 16:22 | 2026-07-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $28.42 | -10.0K | 362.2K | -3% | -$284.2K |
| DT | 2026-05-20 16:07 | 2026-05-18 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +15.0K | 377.2K | +4% | +$56.8K |
| DMT | 2026-05-20 16:07 | 2026-05-18 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $20.04 | -15.0K | 362.2K | -4% | -$300.6K |
| DMT | 2026-04-20 19:27 | 2026-04-16+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $4.24 | +37.8K | 377.2K | +11% | +$160.2K |
| DT | 2026-04-20 19:27 | 2026-04-20 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $23.61 | -15.0K | 362.2K | -4% | -$354.1K |
| DM | 2026-03-20 | 2026-03-18+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $18.82 | -15.0K | 339.4K | -4% | -$282.4K |
| DM | 2026-03-20 | 2026-03-18+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +15.0K | 345.9K | +5% | +$56.9K |
| D | 2026-03-11 | 2026-03-09 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $19.17 | -36.8K | 339.4K | -10% | -$704.8K |
| D | 2026-03-11 | 2026-03-09 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +36.8K | 376.2K | +11% | +$139.3K |
| DM | 2026-03-06 | 2026-03-04+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +8,234 | 341.2K | +2% | +$31.2K |
| DM | 2026-03-06 | 2026-03-04+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $18.74 | -8,234 | 339.4K | -2% | -$154.3K |
| D | 2025-12-18 | 2025-12-16 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $5.45 | +29.5K | 339.4K | +10% | +$160.8K |
| D | 2025-11-25 | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $18.86 | -41.2K | 309.9K | -12% | -$776.3K |
| D | 2025-11-25 | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +41.2K | 351.1K | +13% | +$156.0K |
| D | 2025-10-20 | 2025-10-16 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $18.83 | -24.1K | 309.9K | -7% | -$453.9K |
| D | 2025-10-20 | 2025-10-16 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +24.1K | 334.0K | +8% | +$91.4K |
| DM | 2025-10-15 | 2025-10-13+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | S - Sale+OE | $18.88 | -24.7K | 309.9K | -7% | -$466.9K |
| DM | 2025-10-15 | 2025-10-13+ | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO, Dir | M - OptEx | $3.79 | +24.7K | 321.3K | +8% | +$93.7K |
Purchase Sale Sale after option exercise All abbreviations